Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion to recommend the variation to the terms of the marketing authorization for Eli Lilly's Alimta.
Subscribe to our email newsletter
Alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.